MeadowBrook Investment Advisors LLC Has $206,000 Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

MeadowBrook Investment Advisors LLC lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 40.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,305 shares of the medical equipment provider’s stock after purchasing an additional 660 shares during the period. MeadowBrook Investment Advisors LLC’s holdings in Lantheus were worth $206,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the period. Moloney Securities Asset Management LLC acquired a new position in Lantheus during the third quarter valued at $1,066,000. Massachusetts Financial Services Co. MA acquired a new position in Lantheus during the third quarter valued at $25,955,000. Van ECK Associates Corp raised its position in Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after buying an additional 21,604 shares during the period. Finally, Empirical Asset Management LLC acquired a new position in Lantheus during the fourth quarter valued at $323,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on LNTH shares. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial reissued a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group initiated coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Stock Performance

LNTH opened at $81.92 on Wednesday. The company has a market cap of $5.70 billion, a PE ratio of 13.63 and a beta of 0.44. The stock has a 50-day moving average of $91.89 and a 200-day moving average of $98.24. Lantheus Holdings, Inc. has a 52-week low of $54.69 and a 52-week high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.